Ferroptosis as a potential therapeutic target for age-related macular degeneration

Liu, Dongcheng; Liu, Ziling; Liao, Hongxia; Chen, Zhe-Sheng; Qin, Bo

doi:10.1016/j.drudis.2024.103920

Cited by 8 publications

(1 citation statement)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, iron is involved in maintaining the antioxidant balance of the retina, helping to eliminate free radicals and protect the retina from oxidative damage ( 28 ). However, disruptions in iron metabolism can lead to iron deposition and lipid peroxidation, which may have a negative impact in age-related macular degeneration ( 29 ). Therefore, the balance of iron ions is vital for retinal health, and excessive light exposure may cause iron metabolic disorders and harmful oxidative stress, damaging retinal cells.…”

Section: Characteristics Of Ferroptosismentioning

confidence: 99%

Ferroptosis: a novel mechanism of cell death in ophthalmic conditions

Yang,

Lin,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Ferroptosis, a new type of programmed cell death proposed in recent years, is characterized mainly by reactive oxygen species and iron-mediated lipid peroxidation and differs from programmed cell death, such as apoptosis, necrosis, and autophagy. Ferroptosis is associated with a variety of physiological and pathophysiological processes. Recent studies have shown that ferroptosis can aggravate or reduce the occurrence and development of diseases by targeting metabolic pathways and signaling pathways in tumors, ischemic organ damage, and other degenerative diseases related to lipid peroxidation. Increasing evidence suggests that ferroptosis is closely linked to the onset and progression of various ophthalmic conditions, including corneal injury, glaucoma, age-related macular degeneration, diabetic retinopathy, retinal detachment, and retinoblastoma. Our review of the current research on ferroptosis in ophthalmic diseases reveals significant advancements in our understanding of the pathogenesis, aetiology, and treatment of these conditions.

show abstract

Section: Characteristics Of Ferroptosismentioning

confidence: 99%

Ferroptosis: a novel mechanism of cell death in ophthalmic conditions

Yang,

Lin,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Melanin‐Like Nanomedicine Functions as a Novel RPE Ferroptosis Inhibitor to Ameliorate Retinal Degeneration and Visual Impairment in Dry Age‐Related Macular Degeneration

Huang,

Deng,

Wang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Ferrous ion accumulation and lethal oxidative stress mediate irreversible retinal pigment epithelial (RPE) cell ferroptosis and subsequent photoreceptor degeneration, a potential key pathogenic factor in the onset of dry age‐related macular degeneration (dAMD), causing irreversible vision loss in the global elderly population. However, currently, no effective interventional treatment strategy exists in clinical practice. Herein, lesion site‐targeted melanin‐like nanoparticles, named ConA‐MelNPs, are designed as a novel ferroptosis inhibitor for retinal degenerative diseases. ConA‐MelNPs possessed chelating iron ion characteristics, alleviating severe mitochondrial damage caused by oxidative stress and protecting RPE cells from ferroptosis induced by sodium iodate (NaIO3). In a preclinical dAMD mouse model, a single intravitreal injection of ConA‐MelNPs yielded significant responses in electroretinograms and visually‐driven optomotor responses in visually impaired mice, resisting the challenge posed by secondary NaIO3‐induced injuries, with the long‐term sustainability of its therapeutic effect. Mechanistically, ConA‐MelNPs achieve a therapeutic effect by interrupting the detrimental cascade involving “RPE cell ferroptosis, lethal oxidative stress, and microglial proinflammatory activation,” affording the restoration of retinal homeostasis. The synthesized ConA‐MelNPs demonstrated good biosafety, with no detected ophthalmic or systemic side effects. Collectively, ConA‐MelNPs are proposed as a promising therapeutic option for atrophic retinal diseases such as dAMD.

show abstract